10 Best Growth Stocks to Buy for the Next 2 Years

8. Gilead Sciences Inc. (NASDAQ:GILD)

EPS Forward Long Term Growth (3-5 Year CAGR): 21.97%

Number of Hedge Fund Holders: 71

Gilead Sciences Inc. (NASDAQ:GILD) is one of the best growth stocks to buy for the next 2 years. On August 22, Gilead Sciences, through its subsidiary Kite, announced its acquisition of Interius BioTherapeutics, which is a specialist in in vivo cell therapy, for $350 million in cash.

The acquisition will integrate Interius’s in vivo platform into Kite’s existing cell therapy framework to develop a new approach to CAR T-cell therapy where the cells are generated directly inside the patient’s body through a single intravenous infusion. This eliminates the need for the traditional ex vivo process, as well as the need for preconditioning chemotherapy.

Gilead’s acquisition of Interius aims to build upon its two existing FDA-approved CAR T-cell therapies, Yescarta (axicabtagene ciloleucel) and Tecartus (brexucabtagene autoleucel), which are used for certain types of blood cancer. Interius was spun out of the University of Pennsylvania and was the first biotech to advance an in vivo CAR T-cell therapy into a clinical trial.

Gilead Sciences Inc. (NASDAQ:GILD) is a biopharmaceutical company that discovers, develops, and commercializes medicines in the areas of unmet medical need in the US, Europe, and internationally.